Compulsory Licensing of Pharmaceuticals in High‐Income Countries: A Comparative Analysis-Reference-Cited by-同舟云学术

Compulsory Licensing of Pharmaceuticals in High‐Income Countries: A Comparative Analysis

Published:2022-03 Issue:1 Volume:100 Page:284-313
ISSN:0887-378X
Container-title:The Milbank Quarterly
language:en
Short-container-title:Milbank Quarterly

Author:

QUNAJ LINDOR¹,KALTENBOECK ANNA²,BACH PETER B.²

Affiliation:

1. Montefiore Medical Center Albert Einstein College of Medicine

2. Center for Health Policy and Outcomes Memorial Sloan Kettering Cancer Center

Publisher

Wiley

Subject

Public Health, Environmental and Occupational Health,Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1468-0009.12557

Reference36 articles.

1. MulcahyAW et al.International prescription drug price comparisons: current empirical estimates and comparisons with previous studies.Research report.Santa Monica CA:RAND Corporation;2021.

2. Paying for prescription drugs around the world: why is the U.S. an outlier? Issue briefs;Sarnak DO;Commonwealth Fund,2017

3. Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs

4. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation

5. Why Are Drugs Cheaper in Europe?The Wall Street Journal. October 28 2018.https://www.wsj.com/articles/why‐are‐drugs‐cheaper‐in‐europe‐1540760855. Accessed December 8 2021.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Compulsory Licensing or Disclosure Requirement? A Policy Instrument for Tackling Biopiracy in Southeast Asia;Journal of East Asia and International Law;2023-05-01